ArticleTranslational vision science & technology2025
Serum Uric Acid and Intermediate Age-Related Macular Degeneration: A Nationally Representative Study in the United States.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to investigate the associations between serum uric acid (SUA) levels and intermediate age-related macular degeneration (iAMD) in the United States population. Methods: This study included data from the 2005 to 2008 National Health and Nutrition Examination Survey. Weighted logistic regression models (crude, partially adjusted, and fully adjusted) were used to assess linear associations between SUA levels and iAMD. Restricted cubic spline (RCS) analysis tested nonlinear associations. Subgroup analyses stratified by age, sex, and race/ethnicity further explored potential effect modifiers. Results: Among 3208 participants aged ≥50 years, 420 (11.2%) had iAMD and 766 (22.3%) exhibited hyperuricemia (HUA). Logistic regression models showed no significant associations between SUA levels and the odds of developing iAMD across all three models. In the fully adjusted model, the odds ratio (OR) comparing the highest to the lowest SUA quintile was 0.95 (95% confidence interval [CI] = 0.53-1.70, P = 0.84). The trend test indicated no significant increase in the odds of iAMD across quintiles of SUA levels (P for trend = 0.60). Similarly, no significant association was found when SUA values were categorized as HUA or non-HUA (P = 0.66). RCS analysis did not demonstrate a nonlinear relationship between SUA levels and iAMD risk. Subgroup analyses showed no significant differences across age, sex, and race/ethnicity stratifications. Conclusions: Elevated SUA levels were not associated with increased iAMD risk in this large, nationally representative sample. Translational Relevance: Our study provides insights into the relationship between SUA levels and iAMD, challenging "hyperuricemic AMD" and offering valuable implications for clinical risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.